Table 2.
Details of procedures undergone by the patients
| IAT (n = 32) | PVE (n = 25) | IAT & PVE (n = 29) | P-value | |
|---|---|---|---|---|
| Portal vein embolization | ||||
| Vein(s) occluded | ||||
| Right portal vein; n | – | 20 | 26 | 0.350 |
| Left portal vein; n | – | 2 | 0 | |
| Right portal vein+left segment 4; n | – | 3 | 3 | |
| Embolization material | – | |||
| N-butyl cyanoacrylate; n | – | 22 | 12 | 0.014 |
| Microspheres; n | – | 1 | 9 | |
| Coils+polyvinyl alcohol; n | – | 2 | 6 | |
| Procedure-related complications; n | – | 3 | 0 | 0.093 |
| Intra-arterial therapy regimen 1 | ||||
| Extent of tumour | ||||
| Unilobar; n | 20 | – | 18 | 0.941 |
| Bilobar; n | 12 | – | 11 | |
| Chemotherapy regimen | – | |||
| Cisplatin+doxorubicin+mitomycin C; n | 22 | – | 10 | 0.010 |
| Doxorubicin DEB; n(%) | 10 | – | 19 | |
| Procedure-related complications; n | 1 | – | 1 | 0.902 |
| Accompanied systemic chemotherapy; n | 1 | – | 4 | 0.181 |
| Intra-arterial therapy regimen 2 | ||||
| Patients undergoing second IAT; n | 22a | – | 13 | 0.402 |
| Chemotherapy regimen; n | – | |||
| Cisplatin+doxorubicin+mitomycin C; n | 18 | – | 2 | <0.001 |
| Doxorubicin DEB; n | 4 | – | 11 | |
| Procedure-related complications; n | 0 | – | 1 | |
| Accompanied systemic chemotherapy; n | 0 | – | 3 | 0.040 |
| Surgical resection | ||||
| Patients undergoing surgery; n | 0 | 19 | 27 | <0.001 |
| Type of operation | ||||
| Hemi-hepatectomy | – | 7 | 15 | 0.171 |
| Extended resection | – | 12 | 12 | |
| Margin status | – | |||
| R0 | – | 19 | 26 | 0.594 |
| R1 | – | 0 | 1 | |
| Procedure-related complications; n | – | 6 | 8 | 0.891 |
| Operative mortality, n | – | 1 | 2 | 0.190 |
a
From a total of 31 patients. One patient had complications arising from the first IAT.
IAT, intra-arterial therapy; PVE, portal vein embolization; DEB, drug-eluting beads.